USE OF ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION: A SYSTEMATIC REVIEW
DOI:
https://doi.org/10.51473/rcmos.v1i1.2024.640Keywords:
Anticoagulants. Atrial fibrillation. Safety. Stroke prevention. WarfarinAbstract
Atrial fibrillation (AF) is one of the most prevalent cardiac arrhythmias, associated with a high risk of thromboembolic complications such as stroke. The use of anticoagulants is essential to prevent these events, with warfarin being widely used for many years. However, new oral anticoagulants (NOACs), such as apixaban and rivaroxaban, have emerged as safer
and more effective alternatives, especially in vulnerable subgroups like patients with chronic
kidney disease and the elderly. This study reviews recent literature on the use of anticoagulants in AF patients, comparing NOACs with warfarin in terms of efficacy, safety,
and adherence. Nine studies were selected from PubMed and ScienceDirect databases. The
results indicate that NOACs have a better safety profile concerning hemorrhagic events and are easier to use due to the lack of frequent monitoring requirements. However, warfarin is still widely used, especially in lower-income countries, due to its more accessible cost. It is concluded that while NOACs represent a significant advancement in AF management, their widespread implementation depends on financial accessibility and the individual suitability of
each patient.
Downloads
References
ABILDGAARD, A. et al. Dosage of Anticoagulants in Obesity: Recommendations Based on a Systematic
Review. Semin Thromb Hemost, v.46, p.932-969, 2020.
FATIMA, H. et al. Safety and Efficacy of Apixaban vs Warfarin in Patients With Stage 4 and 5 Chronic Kidney
Disease: A Systematic Review. Cureus, v.14, p.e30230, 2022.
KUNO, T. et al. Oral Anticoagulation for Patients With Atrial Fibrillation on Long-Term Hemodialysis. J Am
Coll Cardiol, v.75, p.273-285, 2020.
LIN, D. S. et al. Efficacy and Safety of Direct Oral Anticoagulants for Stroke Prevention in Older Patients With
Atrial Fibrillation: A Network Meta-Analysis of Randomized Controlled Trials. J Am Heart Assoc, v.12,
p.e030380, 2023.
MARON, B. J. et al. Management of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll
Cardiol, v.79, p.390-414, 2022.
PROIETTI, M. et al. Frailty Prevalence and Impact on Outcomes in Patients with Atrial Fibrillation: A
Systematic Review and Meta-Analysis of 1,187,000 Patients. Ageing Res Rev, v.79, p.101652, 2022.
VAN DEN EYNDE, J. et al. Thromboprophylaxis in Patients With Fontan Circulation. J Am Coll Cardiol, v.81,
p.374-389, 2023.
WANG, D. et al. Clinical Benefits of Oral Anticoagulants in Atrial Fibrillation Patients with Dementia: A
Systematic Review and Meta-analysis. Front Cardiovasc Med, v.10, p.1265331, 2023.
WANG, M. K. et al. Use of Anticoagulation Therapy in Patients With Perioperative Atrial Fibrillation After
Cardiac Surgery: A Systematic Review and Meta-analysis. CJC Open, v.4, p.840-847, 2022
Downloads
Additional Files
Published
Issue
Section
Categories
License
Copyright (c) 2024 Lara Vitória de Paula Oliveira, Cristiano Frattesi Bernardes, Izabela Regina França Ribeiro, Paulo Roberto de Oliveira Santos (Autor/in)
This work is licensed under a Creative Commons Attribution 4.0 International License.
This work is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This means you are free to:
- Share — copy and redistribute the material in any medium or format.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The use of this material is conditioned upon proper attribution to the original author(s), providing a link to the license, and indicating if changes were made. The license does not require permission from the author or the publisher as long as these conditions are met.
The Creative Commons license logo is displayed permanently in the footer of the journal.
The copyright of the manuscript can be retained by the authors without restrictions and can be requested at any time, even after publication in the journal.
How to Cite
